Tamsulosin
- Generic Name
- Tamsulosin
- Brand Names
- Flomax, Jalyn
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5S
- CAS Number
- 106133-20-4
- Unique Ingredient Identifier
- G3P28OML5I
- Background
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor mus...
- Indication
Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus
- Associated Therapies
- -
Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2015-05-14
- Lead Sponsor
- Diskapi Teaching and Research Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02443844
- Locations
- 🇹🇷
Turkish Ministry of Health Dıskapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Silodosin Versus Tamsulosin for Treatment of Ureteral Stones
- Conditions
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Albert Einstein Healthcare Network
- Target Recruit Count
- 1
- Registration Number
- NCT02369744
- Locations
- 🇺🇸
Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States
Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.
- Conditions
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- St. Joseph's Healthcare Hamilton
- Target Recruit Count
- 200
- Registration Number
- NCT02279615
- Locations
- 🇨🇦
St. Joseph's Healthcare Hamilton - McMaster Institute of Urology, Hamilton, Ontario, Canada
Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 97
- Registration Number
- NCT02266537
Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02264184
Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 982
- Registration Number
- NCT02245529
Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 493
- Registration Number
- NCT02244242
Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7391
- Registration Number
- NCT02245503
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4150
- Registration Number
- NCT02244320
Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms
- Conditions
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT02244281
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.